OHSU Rhesus macaque embryo research to improve Preimplantation Genetic Diagnosis

Preimplantation Genetic Diagnosis is used by parents to screen embryos produced through in-vitro fertilization (IVF) in order to ensure that the baby will be free of specific genetic diseases.  New research from Oregon Health and Science University on the inheritance of the mitochondrial genome indicates that screening for genetic mutations that are located in the genome of the mitochondria – which is outside the nucleus of the cell where the much larger chromosomal genome id found, and is inherited only from the mother – can be made more accurate by carrying out the screening procedure slightly later than is now the practice.

Dr. Shoukhrat Mitalipov, who led this research project, explains what the project involved and its implications

A press release from OHSU highlights the importance of the Rhesus macaque to this discovery about the inheritance of mitochondial genomes:

“This latest breakthrough, which was conducted in rhesus macaque monkeys because of their similarity to humans, demonstrates the specific stage of early embryonic development when genetic mutations are passed from mother to fetus. This stage, referred to by scientists as “the bottleneck,” occurs when an early embryo called blastocyst, transitions into a fetus.

To conduct the research, Mitalipov and colleagues needed to design a way to mark and track specific mitochondrial genes as they transitioned from egg, through fertilization, to embryo and then to fetus. This was accomplished by combining two separate mitochondrial genomes into one egg cell. More specifically, one-half of an egg cell from a species of Indian-continent rhesus macaque monkey was merged with one-half of an egg cell from a Chinese-continent monkey. Because these animal species have distinct mitochondrial gene sequences (like breeding two distinct species of dogs), their genetics could be tracked closely.

The microscopic manipulation of splitting and uniting two halved egg cells takes specialized skills and expertise, which the Mitalipov lab has developed over a period of several years.

By studying the development of these joined and then fertilized eggs, scientists were surprised to see that eggs transitioned from containing a 50/50 split of genetics to a fetus that contained a nearly 100 percent either Indian or Chinese-based genome.

 We discovered that during early development, each individual cell in the eight-cell embryo would contain varying percentages of the Indian and Chinese rhesus genes. Some would be a 50/50 split. But others would be 90/10 and so on,” explained Mitalipov. “When these percentages were combined as a whole embryo, the average genetic split between the two species was about equal as initially created. However, later during the transition from a blastocyst to fetus, the genetics would swing one way or another. The resulting offspring would have always a genome that is predominantly Chinese or Indian. Our study tells us precisely when this mitochondrial gene switch occurs and how this can lead to disease.”

This finding raises significant questions about validity of currently methods for genetic diagnosis in early embryos, when a woman is known to carry a mitochondrial gene mutation may pass a disease to her children.

The current pre-implantation genetic diagnosis method is to examine genetic disease risk is by taking one cell from an early eight-cell embryo, and then looking for mutations in that one particular cell. This is done to predict if the remaining embryo is mutation-free,” explained Mitalipov.

The problem with this approach is that you may choose a cell that may not have mutations. But that does not mean the remaining cells in an embryo are mutation-free. Our research suggests that such approach could be flawed because diagnosis takes place prior to the stage when an offspring’s mitochondrial genetics is truly established.”

With this new information and with additional data gathered through further research, Mitalipov and colleagues believe that new methods for genetic diagnosis for mitochondrial disease should be located. The research also demonstrates that the Mitalipov lab’s previously developed method for preventing the passing of mitochondrial mutations from mother to child is highly successful.”

It’s an important discovery, one with important implications for preimplantation genetic diagnosis, and we congratulate Dr. Mitalipov and his colleagues at OHSU on their success!

Lee, H., Ma, H., Juanes, R., Tachibana, M., Sparman, M., Woodward, J., Ramsey, C., Xu, J., Kang, E., Amato, P., Mair, G., Steinborn, R., & Mitalipov, S. (2012). Rapid Mitochondrial DNA Segregation in Primate Preimplantation Embryos Precedes Somatic and Germline Bottleneck Cell Reports DOI: 10.1016/j.celrep.2012.03.011

Dogs in Medical Research

A video clip from Understanding Animal Research, a UK organisation which tries to tackle some of the misunderstandings about animal research. This kind of open advocacy which allows people to see the conditions of animals in labs is an important step in winning and keeping public support for lifesaving medical research.

Notice the use of clicker training to get the animals to do simple tasks such as jump on the weighing scales – this reduces any stress that might be caused by trying to force the beagle to do this unwillingly. This is just one of the many enrichment techniques used to improve animal welfare in laboratories around the world.

An excellent example of the value of dogs in biomedical research is provided by a BBC report “‘Heart shrinking’ trial to combat heart failure to begin” on the launch of a multi-centre trial (see clinicaltrials.gov for details) to evaluate whether electrical stimulation of the vagus nerve can reduce cardiac hypertrophy and arrhythmia, and improve heart function in patients with heart failure. The BBC report acknowledges that “The technique is being trialled in humans after it was shown to keep rats and dogs alive for longer” and links to a 2003 paper which found that electrical stimulation of the vagus nerve increases survival in a rat model of cardiac hypertrophy.

This  technique is based on a discovery made in 1984 (1), when scientists showed that an imbalance in the autonomic nervous system – part of the nervous system that acts as a control system functioning and is comprised of parasympathetic nervous system (PSNS) and sympathetic nervous system (SNS) – has a critical role in the induction of lethal ventricular arrhythmias in dogs following heart attack, with an increase in SNS activity leading to abnormal heart rate, heart tissue growth, and heart failure. Over the past decades several drugs have been developed to treat heart failure by reducing heart tissue growth – the ‘heart shrinking’ referred to in the BBC report – and heart rate, for example Ivabradine whose development we discussed recently, but more recently another approach has received attention, modulating the PSNS through stimulation of the vagus nerve in order to rebalance the autonomic nervous system inputs into the heart.

Following a series of studies which demonstrated that stimulation of the vagus nerve could prevent death and improve heart function in a variety rat and dog models of cardiac dysfunction and heart failure (including the study mentioned by the BBC above), scientists demonstrated in that the beneficial effect of vagus nerve stimulation was additive when combined with drugs to treat heart failure in dogs. An open access review of these studies published in 2010 (2) by Professor Peter J Schwartz of the University of Pavia notes that:

An impressive aspect of these experimental studies is that they provide an unusually uniform picture of significant positive effects produced by chronic vagal stimulation in the failing heart. Furthermore, they also provide evidence for the important concept that the mechanism(s) underlying the protective effect of vagal stimulation involve something at least in part independent of the heart rate slowing.”

This result supported a decision to launch the first small phase I clinical trial of this technique in patients with heart failure, led by Professor Schwartz (3), which demonstrated the safety of the technique, and provided early hints of its effectiveness in 8 human patients. The much larger study whose launch was by the BBC uses a device manufactured by Boston Scientific rather than the BioControl Medical device used in the earlier study led by Prof. Schwartz, but is development was equally dependent on the same careful research in dog models of cardiac disease and heart failure.

It’s just one of many examples of why lab such as the one  in the Understanding Animal Research video are so valued by the medical research community.

Regards

Tom Holder

1)      Schwartz PJ, Billman GE, Stone HL. “Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with healed myocardial infarction. An experimental preparation for sudden cardiac death.” Circulation. 1984 Apr;69(4):790-800.PubMed: 6697463

2)      Schwartz PJ.”Vagal stimulation for heart diseases: from animals to men. – An example of translational cardiology.-.” Circ J. 2011;75(1):20-7. PubMed: 21127379.

3)      Schwartz PJ, De Ferrari GM, Sanzo A, Landolina M, Rordorf R, Raineri C, Campana C, Revera M, Ajmone-Marsan N, Tavazzi L, Odero A. “Long term vagal stimulation in patients with advanced heart failure: first experience in man.” Eur J Heart Fail. 2008 Sep;10(9):884-91. PubMed 18760668

Schwartz, P. (2011). Vagal Stimulation for Heart Diseases: From Animals to Men Circulation Journal, 75 (1), 20-27 DOI: 10.1253/circj.CJ-10-1019

 

What GM mice can tell us about pancreatic cancer (and medical charities)

I’ve written on the growing importance of genetically modified (GM) mice in cancer research before, but it’s been a little while since I revisited the subject. So when I saw this BBC story yesterday on how scientists at the Cancer Research UK Cambridge Research Institute has used an elegant study in GM mice to identify a gene whose suppression contributes to the development of pancreatic ductal adenocarcinoma – one of the most lethal cancers – I was all set to write a blog post about it.

Then I noticed that Kat Arney at the Cancer Research Science Blog had beaten me to it, with an excellent overview of the study and its implications. I recommend that you go straight over and read her blog post.

The Nature paper describing this study can be read here.

A fascinating aspect of this work is that human genetic studies had failed to reveal the role of the Usp9x gene in pancreatic cancer, and it was only when the GM mice studies were undertaken that its importance became clear.  Does this mean that the human genetic studies were misleading? Does it mean that they were useless? Well, that would be thinking like an anti-vivisectionist.  While it’s true that the human genetic studies were initially misleading about Usp9x in pancreatic cancer, it was by combining the information from human genetic studies with that from the GM mouse studies, and the additional information from in vitro studies, that the mechanism through which Usp9x suppression contributes to the development of pancreatic cancer was revealed.

This is yet another example of the important role played by animal studies alongside  many other approaches in medical research, and I hope that it soon leads to much -needed improvments in therapy for pancreatic cancer.

There’s another aspect to this story that is almost as interesting as the science itself.  Many animal rights activists like to claim that leading medical research charities conceal their funding of animal research, indeed just the other week the animal rights activist Peter Tatchell wrote a truly execrable article in the Huffingdon Post which included the claim that:

A disturbing desire for secrecy about animal experiments is shared by a number of respected, high-profile medical charities, including the British Heart Foundation, Cancer Research UK and the Alzheimer’s Society. “

Several comments quickly pointed out that this (along with most other aspects of the article) was factually incorrect, indeed it is difficult to see how the British Heart Foundation could be more open about their animal research. So far as Cancer Research UK is concerned, perhaps somebody should ask Peter Tatchell how issuing a press release, and then discussing their animal research with the BBC and in more detail on their science blog is compatible with “desire for secrecy about animal experiments “.  I guess that Peter Tatchell isn’t one to let the facts ruin a good spin!

Paul Browne

The Golden Goose Awards

Politicians sometimes deride research based on the what they perceive as being “silly” titles of federal funded grants.  If they spot a title that deals with “games”, for example, they may assume it deals with some sort of amusement of little value to society, instead of a deep, powerful branch of mathematics that describes the behavior of competing rational agents with much relevance to voting, economics, cooperation, and so on.  Animal rights activists also enjoy the hobby.  The latest example is IDA’s list of “ridiculous research” ,whose claims were sadly repeated by far too many news journalists who were clearly too lazy check if they were accurate.  There were some honorable exceptions, notably an excellent editorial entitled “When the facts ruin a good spin” in the Times Union, which discusses a project on the role of music as a conditioning stimulus for drug use ends with a statement with which we heartily agree:

What’s “ridiculous,” to borrow the press release’s language, is that we fall for it, over and over, egged on by politicians eager to score easy points. And what’s “wasteful” is the time and energy that could be so much better spent on something other than a cheap shot.”

Back in 1976 the House Committee on Appropriations asked the National Science Foundation “Why does the Foundation persist in supporting research whose results have no apparent value to the American people?“  The NSF responded in part that:

Basic research seeks an understanding  of the laws of nature  without  initial  regard  for specific  utilitarian  value. Ultimately, however, it  is of the  most important  practical significance, because in a broad sense it is the foundation upon  which rests  all technological development.  Applied research builds on the results of basic research, seeking detailed  information  about  a specific situation  whose general laws have  been  discovered by  basic  research.  The  final step  toward  utilization  of research-development is  the systematic  application  of knowledge to  the  design  of  end products. [...]

As we  increase  our  knowledge  of nature  and  mankind,  in order  to adjust  nature  to our survival, safety,  comfort and convenience, we must  depend  upon  scientific research  to clarify the  relationships  of many, many things.  Thus,  we study  atoms,  even  though  they  will never  be seen  by an  unaided  human  eye.  We study  stars  too  faint  to  be  seen without  a  telescope  and  with  wavelengths  which  can  only be  detected  with  radio  receivers  or  photographic  plates. To  understand  geology, we must  look  at  geologic formations  and processes in many  parts  of the world where different  conditions have existed.  To understand  more about the  phenomena  of life, we must  study  the  behavior  of viruses,  single  cells,  plants,  and  animals  of  many  species.

A book was compiled covering various areas of research with Isaac Asimov writing an essay defending the value of basic research.

Thus, it was with some surprise and delight that we read in the news about Rep. Jim Cooper (D-Tenn) understanding the value of basic research.  The Washington Post reports that:

On Wednesday afternoon, Cooper rose to the defense of taxpayer-funded research into dog urine, guinea pig eardrums and, yes, the reproductive habits of the parasitic flies known as screwworms–all federally supported studies that have inspired major scientific breakthroughs.

Together with two colleagues he created the Annual Golden Goose Awards to honor federally funded research  “whose work may once have been viewed as unusual, odd, or obscure, but has produced important discoveries benefiting society in significant ways.”

Studying dog urine, among other stuff deem crazy by animal rights cranks, led to major medical discoveries

The article goes on to describe how research on dog urine led to an understanding of the effects of hormones on the human kidney, how studies in the guinea pig led to a treatment for hearing loss in infants, and how studies on the screwworm led to the effective control of the a deadly parasite that targets cattle.  All these provide additional examples refuting the notion that learning about life processes from animals cannot yield knowledge applicable to human health.

The Golden Goose Award has the backing of the American Association for the Advancement of ScienceAssociation of American Universities (who in 2011 published a series of “Scientific Inquirer” articles skewering dubious politically-motivated attacks on basic science) and the Progressive Policy Institute, who are to be congratulated for this excellent initiative to highlight the importance of basic research.

At the press conference to launch the award Rep. Robert Dold told reporters that “When we invest in science, we also invest in jobs. Research and development is a key part to any healthy economy,” while  Rep. Charlie Dent (R-Penn.) added “It’s critical, and the federal government has an important role to play,” who went on to describe how injecting horses with snake venom might “seem peculiar” but led to the discovery of the first anti-venom.

Taking us, once again, to the concluding words of Asimov’s essay:

Unless we continue with science and gather knowledge, whether or not it seems useful on the spot, we will be buried under our problems and find no way out.  Today’s science is tomorrow’s solution — and tomorrow’s problems , too — and, most of all, it is mankind’s greatest adventure, now and forever.

Restoring vision in night blindness: Mice point way to stem cell therapy

Impaired vision and blindness are leading causes of disability, affecting over 3 million people in the USA today, so it’s no surprise that biomedical scientists are working hard to develop therapies to improve and restore vision.  Over the past few years we have discussed several therapies that have been developed to treat different types of vision loss, including anti-angiogenic therapies to treat wet age related macular degeneration, a leading cause of severe, irreversible vision loss in the elderly,  and gene therapy to treat Leber congenital amaurosis, an inherited disease characterised by progressive degeneration of the retina. Speaking of Research committee member Dario Ringach has also written on the Opposing Views website on the very promising research now underway to develop electronic prosthesis to restore vision in blind people.

In another important development in this field Professor Robin Ali* and his team at the UCL Institute of Ophthalmology have announced the first demonstration that transplanted retinal rod cells can improve vision in mice with night-blindness, publishing the results of their study in the prestigious science journal Nature1. Rod cells are photoreceptor cells in the retina of the eye that function well in low light conditions, and an absence of rod cells leads to night blindness. Mutations in the gene GNAT1 cause congenital night blindness in humans, and mice in which the Gnat1 gene has been knocked out are night blind.  In the video below Professor Ali show that by transplanting rod cell precursors into the retina of Gnat1 knockout mice his team was able to restore vision – albeit  not fully.

It’s a fascinating piece of work, though as Professor Ali makes clear in comments to the Guardian newspaper last week there is still a lot of work to do before this can be evaluated in humans.

Now we’ve discovered we can restore vision, it gives us impetus to go on and make the process better”

As both the video and Guardian article indicate an important step will be identifying suitable sources of cells for transplantation, with both embryonic stem cells and induced pluripotent stem (iPS) cells under consideration.  This may not take as long as one might think, as we discussed last November a clinical trial was recently launched to assess the potential for transplantation of another retinal cell type, retinal epithelial cells derived from human embryonic stem cells , to improve vision in patients with  Stargart’s Macular Dystrophy, an inherited form of blindness.

The work of Professor Ali and his colleagues at UCL is moving us closer to an effective treatment – and perhaps it is not unrealistic to talk about a cure – for night blindness. Their work will also no doubt drive research on protoreceptor cell transplantation in other forms of blindness, such as dry age related macular degeneration – the most common cause of vision loss in people aged over 50 – which is characterised by loss of both rod and cone photoreceptor cells.

Paul Browne

*        Professor Ali also played a leading role in the development of gene therapy for Leber congenital amaurosis, and led the first clinical trial of this technique.

1)      Pearson RA, Barber AC, Rizzi M, Hippert C, Xue T, West EL, Duran Y, Smith AJ, Chuang JZ, Azam SA, Luhmann UF, Benucci A, Sung CH, Bainbridge JW, Carandini M, Yau KW, Sowden JC, Ali RR. “Restoration of vision after transplantation of photoreceptors.Nature. 2012 Apr 18. doi: 10.1038/nature10997.

Straight from the animal rights book

It is that time of the year when animal rights activists, will show up at our workplaces dressed in their favorite animal costumes to spread more nonsense and misinformation about the nature of biomedical research.

One of their favorite claims is that the scientific community treats animals like any other piece of disposable, laboratory equipment — such as a Petri dish or a test tube.

Has anyone wondered where do they come up with such an idea?

The notion comes straight from the animal rights books that provide the theoretical foundation for animal rights theory while rejecting more nuanced positions.

A living being is said to have moral status if we are morally obliged to give weight to its interest independent of their utility to us. But what exactly is the moral status of non-human animals? Among the various positions one can take the two extremes are the easiest to describe.

At one end of the spectrum, we find the argument that animals do not truly experience pain, do not have emotions, they do not have interests of their own, and thus they lack moral status.  According to this view humans can do with animals as we please. Given what is known presently about animal cognition and behavior, it would be difficult to find anyone who would seriously defend the Cartesian position.

At the other end of the spectrum, we find those who hold that the moral status of some animals must equal to that of humans. These theories posit that if a living being has some basic properties (such as a minimum level of sentience according Gary Francione, or being the “subject-of-life criterion” according to Tom Regan) they attain the same moral status as that of a normal human: our moral consideration for a mouse, or a dog, or a child, ought to be exactly the same.

And let me assure you — when they say exactly the same, they mean it.

It is evident that most members of the public, including scientists that work with animals in medical research, prefer to position themselves somewhere between the two extremes. These more nuanced positions can be considered to represent different versions of “animal welfarism” which are based on the notion of graded moral status.  In these theories animals would certainly have higher moral status than inanimate laboratory equipment, but not that of humans. Animal anti-cruelty laws, the Animal Welfare Act, and the NIH guidelines as examples of how rules and regulations were established to acknowledge the moral standing of animals (establishing the “forbidden zone” in the spectrum of positions above).

Prominent animal rights philosophers, however, are not happy with shades of gray in moral decision making and attempt to rob others of adopting nuanced positions.

For example, Elizabeth Harman writes:

We have no reason to posit such degrees of moral status, so we can conclude that moral status is not a matter of degree but is rather on/off: a being has moral status or lacks it.

The idea is to reject the concept of graded moral status.

Gary Francione, agrees:

We have two choices – and only two – when it comes to the moral status of animals.

Tom Regan also concurs writing terms of the “inherent value” of animals:

Two options present themselves concerning the possession by moral agents of inherent value. First, moral agents might be viewed as having this value to varying degrees, so that some may have more of it than others. Second, moral agents might be viewed as having this value equally. The latter view is rationally preferable. […] We must reject the view that moral agents have inherent value in varying degrees. All moral agents are equal in inherent value, if moral agents have inherent value.

These philosophers want to force everyone to choose among the two extreme positions — either we accept the animal rights view or we must be cartesians that assign no moral status to the animals.

Thus the activists claim “If you disagree with us then you must be treating the animals as you treat a Petri dish”.

Nonsense.  It is the extreme views that must be rejected instead.

And the above also explains the need for the costumes, the scary masks, the blood-stained coats, the screams and insults, the misinformation and the lies. For these animal rights activists have neither solid philosophical nor scientific arguments to enter into a serious and civil debate on the role of animals in research and how the work has benefited mankind generation after generation.

Mouse study points to effective treatment of Fragile X syndrome

Fragile X syndrome is the most common genetic causes of intellectual disability, affecting about 1 in 4,000 people with more males affected than females, and also the most common genetic cause of autism, being responsible for 2-6% of all cases of autism. While no drugs have yet been approved to treat Fragile X syndrome, there is considerable interest in the biomedical research community in this condition, since as well as being a significant cause of disability in its own right it is a condition whose study may well help medical science to develop effective therapies for other forms of autism.

GM mice have made crucial contributions to our understanding of Fragile X syndrome. Image courtesy of Understanding Animal Research.

Fragile X syndrome is caused by mutations that silence the Fragile X (FMR1) gene and lead to a reduction –or absence – of the fragile X mental retardation protein (FMRP) and by knocking out the corresponding Fmr1 gene in mice and other organisms scientists have been able to generate models for the evaluation of potential therapies for autistic spectrum disorders , such as the drug Arbaclofen whose development we discussed briefly in 2010.

While it was clear quite early on that FMRP plays an important role at the synapse  – the structure that allows nerve signals to be passed from one neuron to another  – the nature of that role was not obvious, though a series of experiments in a variety of animal models had indicated that a class of proteins known as the metabotropic glutamate receptors might be involved.  A key discovery was made by Professor Mark Bear at MIT, who demonstrated that FMRP acted as a counterbalance to metabotropic glutamate receptor sub-type 5 (mGluR5). mGluR5 increases protein synthesis at the synapse as a means to facilitate signal transmission through the brain, and FMRP acts to reduce protein production. In the absence of FMRP signaling at the synapse goes awry, leading to the symptoms observed in fragile X syndrome.  This key scientific breakthrough was made by Prof. Bear by genetically engineering Fmr1 knockout mice halve the production of mGluR5, resulting in a significant reduction in fragile X symptoms in these mice. This linking of alteration in the expression of the gene to changes in fragile X symptoms was an important result, indicating that it may be possible to treat Fragile X by reducing the amount or the activity of mGluR5.

However, using gene modification to knock-down mGluR5 activity in people with Fragile X syndrome is not a practical option at this time, so attention turned to identifying drugs that could block mGluR5.  Last week in a paper in the journal Neuron Prof. Bear’s team, working in collaboration with scientists at the Swiss healthcare company Roche ,announced another major breakthrough. This study used an experimental  mGluR5 inhibitor known as CTEP which had recently been shown in animal studies  to be far more selective for mGlu5 than previous mGluR5, as well as having a longer half-life in vivo making it an ideal candidate for studies where mGLuR5 activity needed to be suppressed for extended continuous periods. They showed that CTEP treatment could not only stop the worsening of the condition but actually reversed the symptoms in FMR1 knockout mice with established Fragile X syndrome (1), including hearing sensitivity, learning and memory, suggesting that the defects in Fragile X syndrome are not irreversible and that it may be possible to effectively treat the cognitive and behavioral disabilities by pharmacological inhibition of mGluR5.

While CTEP is not currently being developed for clinical use, the result of this trial adds further weight to the evidence in favor of mGluR5 inhibition as a means to treat Fragile X syndrome. Two other mGluR5 antagonists – Fenobam and STX 107 – are already being evaluated in early clinical trials following successful evaluation in Fmr1 knockout mice, and this most recent result should encourage further investment in this approach.

The discovery that symptoms can be reversed in established disease in a model of Fragile X syndrome that accurately models the disorder in humans is a major advance, suggesting that the impairments associates with autistic spectrum disorders may not always be permanent  – a result with profound implications for the future of treatment of these disorders.

Paul Browne

1)      Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L. “Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice.” Neuron. 2012 Apr 12;74(1):49-56. PubMed 22500629

sciseekclaimtoken-4f949fa5f1885